Kolltan, The Children's Hospital of Philadelphia deal

Kolltan received an exclusive license from the hospital to IP covering the use of anaplastic lymphoma kinase (ALK) antibodies to inhibit neuroblastoma. Kolltan will also collaborate with the hospital ...